According to the American Cancer Society, as many as 10% of pancreatic cancers are caused by familial and hereditary risk factors. PanFAM-1 is the largest prospective study to date, focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC). Designed to support the road to reimbursement for Immunovia’s blood test, IMMray™ PanCan-d, the study has ended enrollment of new subjects October 30, 2020 from the 23 familial/hereditary pancreatic cancer high-risk surveillance programs in USA and Europe. The study reports the collection of over 3000 blood samples from 1265 subjects. The last blood samples will be collected in April 2021. All blood samples will be analysed in the second half of 2021.
IMMray™ PanCan-d is a complementary method to the two most commonly used testing methods today – Endoscopic ultrasound (EUS) and Magnetic Resonance Imaging (MRI), thus opening the way for novel and more accurate surveillance programs. The main goals of PanFAM-1 are:
- to diagnose pancreatic cancer early
- to provide clinical performance data with IMMray™ PanCan-d from a prospective cohort of high-risk asymptomatic individuals compared with currently used surveillance methods i.e. imaging technologies.
PanFAM-1 was designed in close collaboration with Key Opinion Leaders in pancreatic cancer driving familial risk programs in US and Europe. PanFAM-1 is a multicenter prospective study for early detection of pancreatic cancer in individuals presenting hereditary/familial risk factors. Important milestones of the study include the last subject enrolled on October 30, 2020, last blood samples collected on end of April 2021, and analysis with the validated IMMray™ PanCan-d in the second half of 2021.
There are 23 participating partners in PanFAM-1:
United States: New York University Hospital, NY; Columbia University, NY; Mount Sinai Hospital, NY; Stanford Gastroenterology and Hepatology, CA; Yale University, CT; University of Chicago Medical Center, IL; Massachusetts General Hospital, MA; University of Massachusetts, MA; The Ohio State University, OH; Oregon Health & Science University, OR; University of Pennsylvania, PA; University of Pittsburgh Medical Center, PA and University of Utah, UT. Canada: The Research Institute of the McGill University Health Centre. Sweden: Karolinska University Hospital; Sahlgrenska University Hospital; Umeå University Hospital and Linköping University Hospital. Spain: University Hospital Ramon y Cajal; University Hospital Santiago de Compostela and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL). United Kingdom: University College London Hospital and The University of Liverpool.
- American Society of Clinical Oncology, ’Pancreatic Cancer: Risk Factors’, cancer.net/cancer-types/pancreatic-cancer/risk-factors.
- Mouad E, Guido E, ’Risk factors for pancreatic cancer: underlying mechanisms and potential targets’, Front Physiol. 2014; 5: 490.
- Theodore B, Anna Mae Diehl, ’Advanced Therapy in Gastroenterology and Liver Disease’, PMPH-USA, 2005, s. 825.